Northwell Health Cancer Institute at Rego Park a Program of LIJ

We study how serum and mucosal antibodies protect mammalian hosts from microbial pathogens and toxins. We are interested in next-generation vaccines and adjuvants to combat biothreat agents and enteric diseases.

We use genetics and molecular biology to learn how coronaviruses, a family of RNA viruses including the agents that cause SARS and MERS, replicate their genetic material and assemble into virions during infection.

We study gene regulation in the context of bacterial pathogenesis, with a focus on two pathogens: Mycobacterium tuberculosis, the bacterium that causes TB, and Yersinia pestis, the etiologic agent of bubonic and pneumonic plague.

We develop molecular diagnostic assays and reference testing for the detection and characterization of pathogenic bacteria and mycobacteria and to predict antibiotic resistance using real-time PCR and whole genome sequencing.

We study mosquito-borne arboviruses, focusing on vertical transmission and persistent arboviral infections in mosquitoes. We are also interested in determining the role of RNA-RNA recombination in virus evolution.

We investigate the influence of biofilm growth on the mechanisms of pathogenesis, persistence and drug tolerance in mycobacterial pathogens, with particular emphasis on Mycobacterium tuberculosis.

We focus on simplifying and automating published low-volume newborn screening tests in order to transform them into high-volume assays.

We study the molecular mechanisms by which multiple DNA polymerases replicate bacterial genomes completely, with high accuracy and tolerance for DNA damage, yet also create mutations that give rise to antibiotic resistance.

We study copy number variants (CNVs), which are widespread in the human genome and alter dosage of genes important in conditions ranging from HIV susceptibility to autism spectrum disorders. We seek to compile a catalog of CNVs and their frequencies.

Screening has uncovered individuals whose sweat chloride values are above normal, but no other CF symptoms are identified. Our aim is to determine if other variants in the CFTR gene, or modifier genes, correlate with these abnormal levels.

We study gene regulation in bacteria, with a focus on genome-scale approaches. We are interested in regulation of transcription, the function of non-coding RNAs, and leaderless translation initiation.